i
Cost-effectiveness of Chlamydia Vaccination Programs for Young Women
-
Jun 2015
-
-
Source: Emerg Infect Dis. 21(6):960-968.
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:We explored potential cost-effectiveness of a chlamydia vaccine for young women in the United States by using a compartmental heterosexual transmission model. We tracked health outcomes (acute infections and sequelae measured in quality-adjusted life-years [QALYs]) and determined incremental cost-effectiveness ratios (ICERs) over a 50-year analytic horizon. We assessed vaccination of 14-year-old girls and catch-up vaccination for 15-24-year-old women in the context of an existing chlamydia screening program and assumed 2 prevaccination prevalences of 3.2% by main analysis and 3.7% by additional analysis. Estimated ICERs of vaccinating 14-year-old girls were $35,300/QALY by main analysis and $16,200/QALY by additional analysis compared with only screening. Catch-up vaccination for 15-24-year-old women resulted in estimated ICERs of $53,200/QALY by main analysis and $26,300/QALY by additional analysis. The ICER was most sensitive to prevaccination prevalence for women, followed by cost of vaccination, duration of vaccine-conferred immunity, and vaccine efficacy. Our results suggest that a successful chlamydia vaccine could be cost-effective.
-
Subjects:
-
Source:
-
Document Type:
-
Place as Subject:
-
Volume:21
-
Issue:6
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: